- Release Date: 14/07/15 11:20
- Summary: MONTHLY: NZR: Refining NZ - Margin & Throughput Report - May/June 2015
- Price Sensitive: No
- Download Document 1.45KB
NZR 14/07/2015 11:20 MONTHLY PRICE SENSITIVE REL: 1120 HRS The New Zealand Refining Company Limited MONTHLY: NZR: Refining NZ - Margin & Throughput Report - May/June 2015 Refining NZ's Processing Fee for the first six months of 2015 was NZD 170.9 million, NZD 2.5 million above the full year result for 2014. This is after deducting a Margin Cap of NZD 7.8 million, which is recoverable in the second half of 2015 should the Gross Refinery Margin (GRM) move below the Margin Cap. The year to date throughput of 20.9 million barrels was one million barrels ahead of the 2014 first half throughput. Excellent operational performance and successful completion of the planned shutdown in May resulted in a throughput for May/June of 6.42 million barrels. The GRM - excluding the Cap -for May/June was USD 8.55 per barrel, resulting in a Processing Fee income of NZD 53.4 million or NZD 48.9 million including the Cap. Singapore complex margins remained healthy for the period at an average of USD 4.24 per barrel and Refining NZ's margin uplift over Singapore complex margins was USD 4.31 per barrel. The average exchange rate for the period was USD/NZD 0.72. Appendix I shows further information on throughput, margin and refining income. Historical Analysis A five year history of Throughput, Margins and Processing Fees is attached as Appendix II and can also be found on the company's website: www.refiningnz.com End CA:00266973 For:NZR Type:MONTHLY Time:2015-07-14 11:20:51
- Forums
- NZX - By Stock
- NZR
- Ann: MONTHLY: NZR: Refining NZ - Margin & Throughput Report - May/June 2015
Ann: MONTHLY: NZR: Refining NZ - Margin & Throughput Report - May/June 2015
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug